Enorama Pharma AB (publ) (STO:ERMA)
Sweden
· Delayed Price · Currency is SEK 0.770
+0.096 (14.24%)
Mar 9, 2026, 5:11 PM CET
Enorama Pharma AB Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Revenue | 3.63 | 15.77 | 1.36 | 6.85 | 12.8 | 4.47 | Upgrade
|
| Revenue Growth (YoY) | -72.70% | 1061.12% | -80.17% | -46.50% | 186.40% | -57.17% | Upgrade
|
| Cost of Revenue | 16.47 | 12.07 | 5.26 | 7.46 | 8.9 | 2.1 | Upgrade
|
| Gross Profit | -12.84 | 3.7 | -3.9 | -0.62 | 3.9 | 2.37 | Upgrade
|
| Selling, General & Admin | 39.89 | 31.13 | 34.39 | 37.83 | 29.99 | 24.53 | Upgrade
|
| Other Operating Expenses | -0.2 | -0.24 | -0.01 | -0.02 | -0.15 | 0.53 | Upgrade
|
| Operating Expenses | 57.96 | 51.3 | 37.92 | 41.35 | 31.23 | 25.38 | Upgrade
|
| Operating Income | -70.8 | -47.6 | -41.82 | -41.97 | -27.33 | -23.01 | Upgrade
|
| Interest Expense | -9.55 | -0.43 | -0.88 | -1.27 | -0.8 | -0.45 | Upgrade
|
| Interest & Investment Income | - | 0.14 | 0.08 | - | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | 4.08 | 4.08 | -1.99 | 0.96 | 0.19 | - | Upgrade
|
| Other Non Operating Income (Expenses) | -0.29 | - | - | - | 0.2 | - | Upgrade
|
| EBT Excluding Unusual Items | -76.57 | -43.81 | -44.61 | -42.28 | -27.74 | -23.46 | Upgrade
|
| Pretax Income | -76.57 | -43.81 | -44.61 | -42.03 | -27.74 | -23.46 | Upgrade
|
| Net Income | -76.57 | -43.81 | -44.61 | -42.03 | -27.74 | -23.46 | Upgrade
|
| Net Income to Common | -76.57 | -43.81 | -44.61 | -42.03 | -27.74 | -23.46 | Upgrade
|
| Shares Outstanding (Basic) | 66 | 53 | 28 | 8 | 6 | 6 | Upgrade
|
| Shares Outstanding (Diluted) | 66 | 53 | 28 | 8 | 6 | 6 | Upgrade
|
| Shares Change (YoY) | 37.91% | 91.50% | 253.96% | 26.23% | 11.44% | 3.47% | Upgrade
|
| EPS (Basic) | -1.16 | -0.83 | -1.61 | -5.37 | -4.48 | -4.22 | Upgrade
|
| EPS (Diluted) | -1.16 | -0.83 | -1.61 | -5.37 | -4.48 | -4.22 | Upgrade
|
| Free Cash Flow | -47.77 | -35.7 | -41.35 | -32.96 | -30.22 | -24.51 | Upgrade
|
| Free Cash Flow Per Share | -0.72 | -0.67 | -1.49 | -4.21 | -4.88 | -4.41 | Upgrade
|
| Gross Margin | - | 23.48% | -287.26% | -9.00% | 30.45% | 52.92% | Upgrade
|
| Operating Margin | -1950.50% | -301.87% | -3079.82% | -612.90% | -213.52% | -514.90% | Upgrade
|
| Profit Margin | -2109.39% | -277.82% | -3285.20% | -613.85% | -216.75% | -524.86% | Upgrade
|
| Free Cash Flow Margin | -1316.01% | -226.42% | -3044.85% | -481.35% | -236.14% | -548.47% | Upgrade
|
| EBITDA | -72.51 | -47.16 | -41.15 | -41.3 | -26.67 | -22.69 | Upgrade
|
| EBITDA Margin | - | -299.06% | - | - | -208.34% | - | Upgrade
|
| D&A For EBITDA | -1.7 | 0.44 | 0.68 | 0.67 | 0.66 | 0.32 | Upgrade
|
| EBIT | -70.8 | -47.6 | -41.82 | -41.97 | -27.33 | -23.01 | Upgrade
|
| EBIT Margin | - | - | - | - | -213.52% | - | Upgrade
|
| Revenue as Reported | - | 27.61 | 1.12 | 9.44 | 12.95 | 5.12 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.